Adoption Of Medical Innovations : An International Review

Improvements in health care and life sciences are an important source of gains in health and longevity globally. The development of innovative pharmaceutical products plays a critical role in ensuring these continued gains. To encourage the continued development of new drugs, economic incentives are essential. These incentives are principally provided through direct and indirect government funding, intellectual property laws, and other policies that favor innovation. Without such incentives, private corporations, which bring to market the vast majority of new drugs, would be less able to assume the risks and costs necessary to continue their research and development (R&D). In the United States, government action has focused on creating the environment that would best encourage further innovation and yield a constant flow of new and innovative medicines to the market. The goal has been to ensure that consumers would benefit both from technological breakthroughs and the competition that further innovation generates. The United States also relies on a strong generic pharmaceutical industry to create added competitive pressure to lower drug prices. Recent action by the Administration and Congress has accelerated the flow of generic medicines to the market for precisely that reason. By contrast, in the Organization for Economic Cooperation and

Health care costs are a longstanding concern to policymakers. For years, health care spending has been rising faster than the rate of economic growth, raising the question of what factors are responsible for rising health care costs. This paper explores published articles that report results from research conducted on technological innovations in health care and its relation to rising health care costs. The cost increases have a significant effect on households, businesses, and government programs. Health care experts indicates the development and diffusion of medical technology as primary factors in explaining the persistent

Each product must go through a progression of approval, clinical trials, and post market observation protocols in order to ensure its safety and effectiveness. Stages in the development of medical technologies are scientific background and development of idea for a product, product development, approval, and distribution, diffusion, adoption and utilization of the product. Health care professional, patients, families, and policy makers all struggle to understand how health is affected by behavior, economic and social

The twenty-first century has seen pharmaceutical companies grow in unprecedented size and strength. Due to the unprecedented growth the larger pharmaceutical companies have gained leverage and power in the prescription drug industry, but they lack innovation to market and they seek ways to help the business continue to increase its profits. The pharmaceutical industry was once ethically sound and was a valuable player in the development of human health. However, overtime with the lack of innovation pharmaceutical companies are becoming an unethical market that exploits patients, doctors and anyone else it can to increase its profitability. With eyes only on profitability this can create a hazard for patients because there

One technological change that may have the largest effect on our lives today is the rapid growth of medical technology development. Three main effects that medical technology has impacted our modern society are prolonging lifespan, improving quality of health care and promoting nation’s economic growth. The three stages of medical technology are review by regulatory agencies, technology assessments by insurance carriers, and review by purchasers, clinicians, and consumers. Review by regulatory agencies is the most recognized of the three stages and is administered by the Food and Drug Administration (FDA). The FDA is responsible for protecting and promoting public health by regulating pharmaceutical products and medical devices. Each product must go through a series of approvals, clinical trials, and post market surveillance protocols in order to ensure its safety and effectiveness. www.nap.edu

1 Kaiser Family Foundation Report on the Uninsured. Available at http://www.kff.org/uninsured/7451.cfm. 2 Danzon, P., et al. “The Impact of Price Regulation on the Launch Delay of New Drugs.” Health Economics, 2005; 14(3): 269-292. Available at http://hc.wharton.upenn.edu/danzon/html/Journal_Articles.htm. 3 The Boston Consulting Group. “Ensuring Cost Effective Access to Innovative Pharmaceuticals – Do Market Interventions Work?” April, 1999. Available at http://www.bcg.com/impact_expertise/publications/files/Ensuring_Cost_Effective_Access_Innovative_Pharmaceuticals_Apr1999.pdf 4 Thorpe, K. et al. “Differences in Disease Prevalence as a Source of the U.S.–European Health Care Spending Gap.” Health Affairs (Web Exclusive) Oct. 2, 2007. Available at www.healthaffairs.org.

This survey included over 3,700 physicians in eight different countries. The results showed Canada continuously had the lowest overall adaption rate; early adaption of technologies is a key element to sustaining healthcare systems (Williams). “Canada is a slow adapter of innovative technologies that could enhance the quality of health care services and improve the health and quality of life of Canadians” (Daniel Muzyka).

Medical technology encompasses a wide range of healthcare products and is used to diagnose, monitor, and treat diseases or medical conditions that affect humans. This may included but not limited too, pharmaceuticals, vaccines, and medical equipment. Such technologies are intended to improve the quality of healthcare delivered through earlier diagnosis, less invasive treatment options and reductions in hospital stays and rehabilitation times. Recent advances in medical technology have also focused on cost reduction. Medical technology may include medical devices, information technology, biotech, and healthcare services. The impacts of medical technology may involve social and ethical issues. For example physicians may seek objective information from technology rather than listening to subjective patient reports. A major contributor of healthcare expenditure in America is the advancement of medical technology. According to several studies it is shown that there is a correlation between the nation’s gross domestic product (GDP) and money allocated to healthcare. One of the leading theories is that medical technology is growing faster than expected.

More demand for “better quality” healthcare. New technology may not even be better than the previous technology that has been replaced, but people want the “best”.

An article entitled, Leading Innovation in a Risk-Averse Healthcare Environment, by Michael O’Brien describes how decisions in healthcare innovation are being decided by hospital CFOs because budget plays such a large role in the ability to make health care advancements. Innovation is present on all levels, practitioners are creating new innovative medications and techniques that can boost research funding, CFOs are looking at innovative ways to restructure budgets to meet the rising cost demands and nurses and/or therapists are looking for innovative therapy applications to improve patient outcome and support successful healing once discharged from the hospital. Disruptive innovation is constantly present in medicine since this science is only a practice and is constantly evolving in the presence of new research. As a healthcare leader I encourage my peers to constantly be trying to find innovations in their practice. When a practice becomes stagnant there is limited chance for growth and an individual's motivation can be stunted. “Innovation requires that organizations let go of old work and take on new” (O’Brien, p.113)

Recently, there has been a debate about the high prescription drug prices in the United States. Accounting for 9.7% of the national health expenditure, $329.2 billion was spent on prescription medications ($931 per person) in 2011 (Linton, 2014). So what exactly is the average American getting with their $931? Well, because there is an extraordinary amount of time, effort, and energy that goes into creating, manufacturing, and distributing a new drug, it’s no wonder the prices are so high. But what other costs are folded into the prices of your prescribed medications? This review looks beyond just the research and development costs needed to take a new drug from idea to shelf by examining several journals and other credible, secondary sources, to shed some light on how much pharmaceutical companies are spending to develop, advertise, and sell their drugs.

The second metrics that Medtronic use to determine and track the quality of reporting to governing bodies is the Medtronic Adoption and Adherence Metric. Medtronic Adoption and Adherence Metric is intended to reflect how effective Clinical Connect has been adopted by teams and how effective Clinical Connect is being used for reporting. Clinical Connect is a management reporting software used by teams when engaging physicians and health care providers. Adoption and Adherence metrics measure both a quantitative and qualitative measure to the adoption and adherence of Clinical Connect by multiple Medtronic Teams. The quantitative and qualitative combination measure the volume and type of issues, actions, potential risk, and decisions accurately

Disruptive innovation process is for all businesses and in health care it is proved to be the most useful innovation because it helped in making healthcare available for all and affordable for all. The well design model of business administration used by big industries to cut down the cost and making the expensive technological services and goods available to mass is called "Disruptive Innovation''. This process used in health care has changed the affordability and make it accessible to all general people.

The cost of new medical drugs seems to be accepted by many people who use them. These pharmaceutical companies increase their profits more and more each year because many people assume that it does cost a lot of money for research and development. Where in reality, they are only spending about 15% of their profit margins on research and development alone. A huge percentage of these drugs are actually tested in other countries where people are more willing to do trials with these drugs because they cannot afford them. Not only are there more people who are more willing to try them, but also there is less regulation and oversight when it comes to testing. Conducting these clinical trials overseas not only saves

Over the course of many centuries, medical technology has developed to a great extent. Studies show that recent equipment has evolved more in the last ten to twenty years than in the past thousand years. Before human time, people learned to treat themselves by just using natural substances. Now-a-days, our hi-tech systems in the medical field have been created for the most effective tools for a high level of patient care. While they advance the tools, it will then allow for quicker diagnosis, less pain, and fewer costs, which in the end will help save more lives. Some people are accepting that modern technology can buy them more time to live while others might find it quite alarming because they fear